Term
|
Definition
| act of transferrin cells, tissues or organs from one site to another. |
|
|
Term
|
Definition
| The cells, tissues, or organs. |
|
|
Term
|
Definition
| Donor is the same as host. |
|
|
Term
| Isograft (syngeneic graft) |
|
Definition
| Transplantation between genetically identical donor and host. |
|
|
Term
|
Definition
| transplantation between genetically different donor and host of same species. |
|
|
Term
|
Definition
| Transplantation between genetically different donor and host of different species. |
|
|
Term
| Transplantation rejection |
|
Definition
| immune responseof the hsot attempts to reject transplant as foreign. |
|
|
Term
| Graft-versus-host disease |
|
Definition
| Pathological condition caused by the graft-versus-host reaction, which is the response of mature donor-derived T cells in transplanted bone marrow to the alloantigens of the recipients tissues. |
|
|
Term
| Graft-versus-host reaction |
|
Definition
| T cells in the transplant can attack the recipients tissues. |
|
|
Term
|
Definition
| Antigens that vary between individuals of the same species. |
|
|
Term
|
Definition
| The immune responses against alloantigens. |
|
|
Term
| Major histocompatibility antigens |
|
Definition
| The major alloantigens present in rejections and the ABO blood group antigens. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| determines if a recipient's serum has antibodies against donor RBCs. |
|
|
Term
|
Definition
| Rejection of a mismatched organ. Rejection is so fast the tissues never become vascularized. |
|
|
Term
|
Definition
| Recipient T cell-mediated immune responses can attack transplanted tissues. |
|
|
Term
| Diret pathway of allorecognition |
|
Definition
| Donor organ or graft contains donor APC's. |
|
|
Term
| Indirect pathway of allorecognition |
|
Definition
| Recipient APC's process proteins from the donor and present them on self MHC class II. |
|
|
Term
| Mixed lymphocyte reaction |
|
Definition
| Cellular assay for detecting MHC differences between two individuals. The T cells from one individual proliferate in response to allogeneic MHC molecules on the cells of the other individual. |
|
|
Term
| Minor histocompatibilty antigens |
|
Definition
| Caused by differences at minor histocompatibility loci which cause rejections between HLA-identical siblings. |
|
|
Term
|
Definition
| Where antigen-reactive lymphocytes proliferate in response to alloantigens. |
|
|
Term
|
Definition
| Where immune destruction of the graft takes place. |
|
|
Term
|
Definition
| occur months or years after transplantation. |
|
|
Term
|
Definition
| Prodrug of 6-mercaptopurine, an inhibitor of purine biosynthesis. |
|
|
Term
|
Definition
| prodrug of mycophenolic acid-potent inhibitor of IMP dehydrogenase. |
|
|
Term
|
Definition
| given as part of anti-rejection drug treatment. Converted to prenisolone-inhibits activation of NF-kB and production of inflammatory cytokines. |
|
|
Term
|
Definition
| the most commonly used anti-rejection drug. Blocks expression of IL-2 and IL-2 receptor genes to block T cell proliferation. |
|
|
Term
|
Definition
| An alternative to CsA. Also blocks expression of IL-2 and IL-2 R genes. |
|
|
Term
|
Definition
| A newer drug. Blocks signaling through IL-2R. |
|
|
Term
|
Definition
| monoclonal antibody against the TCR complex. Causes rapid depletion of mature T cells from the circulation probably through phagocytosis by cells with Fc receptors. |
|
|
Term
|
Definition
| Polyclonal antibodies against human T cells produced in horses or rabbits. |
|
|
Term
|
Definition
| monoclonal antibody against CD-20 on B cells. |
|
|
Term
|
Definition
| Replace the entire host hematopoietic system by treating recipient with total-body irradiation and cyclophosphamide to kills cells of host immune system. |
|
|
Term
| Hematopoietic stem cell transplant |
|
Definition
| Use of CD34+ blood cells from donors treated with G-CSF and GM-CSF to mobilize stem cells. |
|
|
Term
| Autologous bone marrow transplant |
|
Definition
| Bone marrow transplantation in which the donor and recipient are the same person. In such cases, bone marrow is removed from the patient, treated in some way to remove diseased or harmful cells, and then reinfused. |
|
|
Term
| Graft versus Leukemia effect |
|
Definition
| The donor T cells tend to clean up any residual activity of the host immune system that didn't get eliminated and also tend to kill off tumor cells that sruvived the irradiation/drug treatment regimen. |
|
|
Term
|
Definition
| The body has a natural ability to protect itself against cancer by recognizing differences between healthy cells and cancer cells. |
|
|
Term
|
Definition
| Causes mice to develop carcinogen-induced tumors earlier and with a greater frequency than normal mice. |
|
|
Term
|
Definition
| Peptide antigens derived from cellular proteins that have undergone a mutation. |
|
|
Term
| Tumor-associated antigens |
|
Definition
| Peptide antigens derived from cellular proteins whose expression was normally confined to embryonic cells or are now overexpressed as compared to the normal cell. |
|
|
Term
|
Definition
| a process by which a person is protected from cancer growth and the development of tumour immunogenicity by their immune system |
|
|
Term
|
Definition
| Designed to direct or enhance an immune response against tumor-specific or associated antigens. |
|
|
Term
|
Definition
| Boost the immune system by using only one antigen, rather than the whole tumor cells that contain many thousands of antigen. |
|
|
Term
|
Definition
| Remove dendritic cells and add peptides, epitopes, proteins, cDNA, and mRNA to them. |
|
|
Term
| Peptide Antibody Transfer |
|
Definition
| Provides therapeutic uses of antibodies for cancer. |
|
|
Term
| Nonspecific immunostimulants |
|
Definition
| There has been some interest in nonspecifically stimulating the immune system as a way of promoting immune responses that might hopefully include reesponses against tumor antigens. |
|
|
Term
|
Definition
| Cells with defective genes are removed from a patient for transfection. The treated cells are then returned to the patients. |
|
|
Term
|
Definition
| Direct administration of a gene or packaged gene to the patient. |
|
|
Term
|
Definition
| Retroviruses have a small RnA genome that has three genes coding for structural proteins required fro viral replication. Proviral DNA is surrounded by two long terminal repeats. |
|
|
Term
|
Definition
| Contain promoter and enhancer functions for viral transcription and are involved in integration of the virus into the host cell genome. |
|
|
Term
|
Definition
| Mutagenesis of DNA by insertion of one or more bases. |
|
|
Term
|
Definition
| Regulator of DNA transcription |
|
|
Term
|
Definition
| DNA sequence that enhances transcription of genes they are near. |
|
|
Term
|
Definition
| Cause infections in humans that are relatively mild, often causing upper respiratory symptoms. However has a consequence, they have the potential to trigger inflammatory responses. |
|
|
Term
|
Definition
| Small parvovirus often foudn in cells infected with adenovirus. Has only a single 4.7 kb single-stranded DNA genome surrounded by a protein coat. |
|
|
Term
|
Definition
| Mix with plasmid DNA and allow it to enter a cell through endocytosis. |
|
|
Term
|
Definition
| Small particles often made of various types of polymers, that for gene therapy purposes, can carry DNA or other molecules and be taken up by cells. |
|
|
Term
|
Definition
| The presence of one gene can turn of another gene. |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
